Glycated hemoglobin News and Research

RSS

Obese patients may receive higher rate of recommended care than normal-weight patients, but not lower

Despite a concern that obese or overweight patients may receive lower quality of health care, an analysis of eight common outpatient quality measures from a sample of nearly 70,000 patients finds no evidence that obese or overweight patients receive inferior care when compared with normal-weight patients, and in fact may receive a higher rate of recommended care on several measures, according to a study in the April 7 issue of JAMA.

8 Apr 2010

Updates from Phase I/IIa clinical trial of DIABECELL treatment in insulin-dependent diabetics

Living Cell Technologies Limited, a global company pioneering the development of a cell implant to treat diabetes, today provided a penultimate update regarding the three-year follow up of its Phase I/IIa clinical trial in Russia of its DIABECELL® treatment in insulin-dependent diabetics.

7 Apr 2010

Orexigen Therapeutics announces submission of Contrave NDA for treatment of obesity

Orexigen® Therapeutics, Inc. announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Contrave® (naltrexone SR/bupropion SR), its investigational drug for the treatment of obesity. The NDA is based on a substantial body of evidence gathered through the Contrave Obesity Research (COR) clinical program, which included over 4,500 patients.

1 Apr 2010

New legislation will increase access to health care, says DDI

Will the newly signed health care legislation create a major shift in how pharmaceutical brand decisions are made? The bill will increase access to health insurance, but many believe the practice of medicine is already in transition, and the bill signed by President Obama will simply accelerate changes already being implemented.

31 Mar 2010

ChemoCentryx undertakes Phase II clinical trial of CCX140

ChemoCentryx, Inc., today announced that it has undertaken a Phase II clinical trial of CCX140, a novel, orally-available small molecule compound designed to specifically target the chemokine receptor known as CCR2.

22 Mar 2010

Humedica, Anceta unveil health care data solutions at AMGA 2010 Annual Conference

Humedica, a next-generation clinical informatics company, and Anceta, the healthcare informatics subsidiary of the American Medical Group Association, today announced the launch of Humedica MinedShare™ Ambulatory as well as AMGA’s Anceta Collaborative Data Warehouse at the AMGA 2010 Annual Conference, taking place now through March 20 in New Orleans.

18 Mar 2010

CoreObjects receives PMI Excellence Award for developing HbA1c Blood Sugar Analysis device

CoreObjects is proud to announce the achievement of the Project Management Institutes "Excellence Award" for their role in helping launch a product that enhances the quality of life for patients suffering from diabetes.

12 Mar 2010

Orexigen Therapeutics reports net loss of $15.0M for three months ended December 31, 2009

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the three months and year ended December 31, 2009.

9 Mar 2010

HbA1c levels help predict future diabetes more accurately than fasting glucose measurements

Measurements of hemoglobin A1c (HbA1c) more accurately identify persons at risk for clinical outcomes than the commonly used measurement of fasting glucose, according to a study by researchers at the Johns Hopkins Bloomberg School of Public Health.

4 Mar 2010

Positive clinical trial results of EndoBarrier Gastrointestinal Liner device announced

GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced initial, positive results from a clinical trial evaluating 12 months of treatment with the EndoBarrier™ Gastrointestinal Liner.

3 Mar 2010

Joint science advisory issues messages for diabetics at risk for heart disease and stroke

The data are inconclusive on heart risks from a class of blood sugar-lowering drugs called thiazolidinediones (TZDs) such as pioglitazone (Actos) or rosiglitazone (Avandia), but the medications should be used with close monitoring from healthcare providers according to a joint science advisory from the American College of Cardiology and the American Heart Association.

24 Feb 2010

Lexicon Pharmaceuticals reports positive results from Phase 2 clinical trials for IBS and type 2 diabetes

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months and year ended December 31, 2009.

23 Feb 2010

Texas Health Dallas offers heart and vascular screening program for women

When Mary Gill went to bed that night, nothing would have made anyone think heart disease — not even Mary. She was thin and 42 years old. She exercised regularly, ate a healthy diet and never smoked.

4 Feb 2010

Tubing-Free Insulin Pump System improves glycemic control in diabetic patients

Albany College of Pharmacy and Health Sciences and The Endocrine Group researchers have concluded that the OmniPod® Insulin Management System significantly improved blood glucose control in diabetes patients who previously received insulin through multiple daily injections. The retrospective study results were published in the latest issue of Infusystems USA, in a study titled, 'Clinical Experience with a Tubing-Free Insulin Pump System.'

2 Feb 2010

Ipsen reports consolidated group sales of €1,032.8M for 2009

Ipsen reported today its sales for the fourth quarter and full year 2009.

1 Feb 2010

ConjuChem Biotechnologies reports financial results for fiscal year ended October 31, 2009

The Company's net loss for the quarter ended October 31, 2009 amounted to $2.5 million or ($0.01) per share, compared to $10.9 million or ($0.04) per share, for the quarter ended October 31, 2008.

29 Jan 2010

Lexicon Pharmaceuticals reports positive results from its LX4211 Phase 2 trial in type 2 diabetic patients

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained positive results from a recently completed Phase 2 study of LX4211 in patients with type 2 diabetes mellitus. LX4211 is a once-per-day, orally-delivered, small molecule drug candidate that inhibits the sodium-dependent glucose transporter 2 (SGLT2), lowering the accumulation of glucose in the body and reducing caloric load.

20 Jan 2010

Evidence suggests insulin pumps may help in maintaining blood glucose levels in type 1 diabetic patients

A new evidence review suggests that using a pump to deliver insulin continuously — instead of taking three or more daily injections — might result in better control of blood sugar for people with type 1 diabetes.

18 Jan 2010

OSA adversely affects glucose control in patients with type 2 diabetes

Obstructive Sleep Apnea (OSA) adversely affects glucose control in patients with type 2 diabetes, according to a study conducted by researchers at the University of Chicago.